Doxorubicin-resistant osteosarcoma: Novel therapeutic approaches in sight?

Claudia M. Hattinger, Marilù Fanelli, Elisa Tavanti, Serena Vella, Chiara Riganti, Piero Picci, Massimo Serra

Research output: Contribution to journalComment/debatepeer-review


High-grade osteosarcoma (HGOS) is the most common malignant tumor of bone. One of the most active drugs for HGOS treatment is doxorubicin, which is invariably included in HGOS chemotherapy protocols together with methotrexate and cisplatin, with the possible addition of ifosfamide. Several studies have shown that HGOS patients may be inherently resistant to doxorubicin or may become unresponsive to this drug during chemotherapeutic treatment. In this review, we will analyze the new and most promising strategies based on doxorubicin regimens for the treatment of HGOS.
Original languageEnglish
Pages (from-to)673-677
Number of pages5
JournalFuture Oncology
Issue number8
Publication statusPublished - Apr 1 2017


  • doxorubicin
  • drug resistance
  • osteosarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Doxorubicin-resistant osteosarcoma: Novel therapeutic approaches in sight?'. Together they form a unique fingerprint.

Cite this